Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous 3-day IV infusion of rh-endostatin plus chemotherapy in advanced NSCLC without driver mutations
ChiCTR2200064150Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of endostar in non-small cell lung cancer (NSCLC), sponsored by Shanghai General Hospital. Primary endpoint: Objective remission rate. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200064150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064150.